Hepatitis E cost-effectiveness of therapy

Revision as of 17:57, 18 September 2017 by WikiBot (talk | contribs) (Changes made per Mahshid's request)
Jump to navigation Jump to search

Hepatitis E Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Hepatitis E from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis E cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis E cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis E cost-effectiveness of therapy

CDC on Hepatitis E cost-effectiveness of therapy

Hepatitis E cost-effectiveness of therapy in the news

Blogs on Hepatitis E cost-effectiveness of therapy

Directions to Hospitals Treating Hepatitis E

Risk calculators and risk factors for Hepatitis E cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Immunocompetent patients are usually able to clear HEV spontaneously, however, immunocompromised and end-stage liver disease patients may develop chronic hepatitis E. For this last group of patients, treatment is limited, and further studies are required to improve current therapy. Because these patients are at risk of developing complications from the disease, therapy and further investigations may be considered cost-effective.

Blood transfusions represent a rare form of transmission of hepatitis E. Screening of blood donations could help further decrease this risk. However, due to the fact that most patients are asymptomatic, further studies are required to evaluate the cost-effectiveness of this measure.[1]

References

  1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J; et al. (2012). "Hepatitis E." Lancet. 379 (9835): 2477–88. doi:10.1016/S0140-6736(11)61849-7. PMID 22549046.

Template:WS Template:WH